A Phase I/IIa Study to Evaluate the Tolerance, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1032 in Patients With Advanced Solid Tumors
Latest Information Update: 03 Jul 2024
At a glance
- Drugs PM 1032 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Biotheus
Most Recent Events
- 04 Jun 2024 Preliminary safety and efficacy resultspresented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 09 May 2023 New trial record